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Abstract
Pancreatic adenocarcinoma, a desmoplastic disease, is the fourth leading cause of cancer-related death in the Western
world due, in large part, to locally invasive primary tumor growth and ensuing metastasis. SPARC is a matricellular protein
that governs extracellular matrix (ECM) deposition and maturation during tissue remodeling, particularly, during wound
healing and tumorigenesis. In the present study, we sought to determine the mechanism by which lack of host SPARC alters
the tumor microenvironment and enhances invasion and metastasis of an orthotopic model of pancreatic cancer. We
identified that levels of active TGFb1 were increased significantly in tumors grown in SPARC-null mice. TGFb1 contributes to
many aspects of tumor development including metastasis, endothelial cell permeability, inflammation and fibrosis, all of
which are altered in the absence of stromal-derived SPARC. Given these results, we performed a survival study to assess the
contribution of increased TGFb1 activity to tumor progression in SPARC-null mice using losartan, an angiotensin II type 1
receptor antagonist that diminishes TGFb1 expression and activation in vivo. Tumors grown in SPARC-null mice progressed
more quickly than those grown in wild-type littermates leading to a significant reduction in median survival. However,
median survival of SPARC-null animals treated with losartan was extended to that of losartan-treated wild-type controls. In
addition, losartan abrogated TGFb induced gene expression, reduced local invasion and metastasis, decreased vascular
permeability and altered the immune profile of tumors grown in SPARC-null mice. These data support the concept that
aberrant TGFb1-activation in the absence of host SPARC contributes significantly to tumor progression and suggests that
SPARC, by controlling ECM deposition and maturation, can regulate TGFb availability and activation.
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Introduction
Pancreatic adenocarcinoma continues to carry a dismal
prognosis with a 5 year survival rate of ,5% in the United States
[SEER]. A major clinical and therapeutic challenge for pancreatic
cancer is the fact that the majority of patients present with
advanced disease [1]. To combat pancreatic cancer in the high
percentage of cases where the primary lesion has already spread
beyond its local borders, it is imperative to understand the
mechanisms driving invasion and metastasis.
SPARC (secreted protein acidic and rich in cysteine) is a
glycoprotein that belongs to the matricellular class of proteins, a
functional family of extracellular proteins involved in the
regulation of extracellular matrix (ECM) deposition and remod-
eling. Although principally non-structural, matricellular proteins
influence the structural integrity and composition of the ECM.
After development, SPARC expression is limited to areas of high
ECM turnover, such as bone and gut [2]. However, SPARC
expression increases during wound-healing, angiogenesis and
tumorigenesis [2,3,4,5,6]. SPARC-null (SPARC2/2) mice display
characteristics suggestive of ECM defects, such as early cataract
development, progressive osteopenia, lax skin and a curly tail [7].
In fact, collagen deposition and fibrillogenesis are disrupted in the
lens capsule and dermis of SPARC2/2 mice [8,9]. These data
suggest that SPARC is required for and mediates ECM deposition,
and thus is critical for appropriate tissue remodeling.
In addition to its function in ECM assembly, SPARC directly
binds to or indirectly regulates several growth factors including
platelet-derived growth factor (PDGF), fibroblast growth factor
(FGF), vascular endothelial growth factor (VEGF) and transform-
ing growth factor b (TGFb) [10,11,12,13,14]. Similar to SPARC,
TGFb is a multifunctional signaling protein implicated in wound-
healing and fibrosis as well as tumor progression and metastasis
[15,16,17]. In fact, data suggests that there is a reciprocal
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TGFb induces the expression of SPARC and, in turn, SPARC
modulates the expression and activity of TGFb [13,14,18,
19,20,21,22]. Additionally, SPARC may regulate growth factor
signaling indirectly by affecting the deposition and composition of
the ECM which, subsequently, controls the bioavailability of
chemokines including TGFb.
Previously, we demonstrated that in an orthotopic murine
model of pancreatic adenocarcinoma, invasion and metastasis was
increased in the absence of host SPARC. Consequently, tumor-
bearing SPARC2/2 mice experienced increased morbidity and
decreased survival. In addition, we observed a clear reduction in
the deposition of fibrillar collagens I and III, basement membrane
collagen IV and the collagen-associated proteoglycan decorin in
tumors grown in SPARC2/2 mice. Paradoxically, tumors grown
in SPARC2/2 mice displayed a significant decrease in microvessel
density and pericyte recruitment despite increases in invasion and
metastasis. Enhanced vascular permeability and perfusion due to
alterations in the vascular basement membrane led to decreased
hypoxia in tumors established in the absence of host SPARC.
Lastly, tumors grown in SPARC2/2 mice displayed enhanced
recruitment of fibroblasts and alternatively-activated (M2) macro-
phages [23] (Table 1).
In the current study, we discovered that Pan02 tumors grown
orthotopically in SPARC2/2 mice have significantly increased
levels of active TGFb1 relative to those grown in wild-type
(SPARC+/+) counterparts. To assess the contribution of excess
active TGFb1 on invasion, metastasis, survival, angiogenesis and
immune modulation in the absence of host SPARC, TGFb1
expression and activation was reduced by treatment with the
angiotensin II type 1 receptor antagonist, losartan [24,25]. We
now report that losartan decreased invasion and metastasis,
abrogated vasodilation, restricted permeability and regulated
immune tolerance in tumor-bearing SPARC2/2 mice, which
effectively restored median survival to that of SPARC+/+ mice. We
provide evidence that the aberrant activation of TGFb1 in the
tumor microenvironment lacking stromal-derived SPARC con-
tributes significantly to the phenotypic alterations observed during
progression of orthotopic Pan02 tumors. We conclude that
TGFb1 is a significant driver of the increased tumor dissemination
and decreased survival observed in tumor-bearing SPARC2/2
animals.
Results
There is enhanced activation of transforming growth
factor beta in tumors grown in SPARC-null mice
We showed previously that orthotopic pancreatic tumor growth
of Pan02 cells is more invasive and metastatic in the absence of
host SPARC and that this confers a decrease in the survival of
Sparc-null (SPARC2/2) mice relative to wild-type (SPARC+/+)
littermates [23,26]. In addition, tumors grown in SPARC2/2
mice displayed alterations in angiogenesis, ECM deposition and
immune cell recruitment. Specifically, although microvessel
density was reduced in tumors grown in the absence of host
SPARC, the vascular basement membrane was compromised
leading to enhanced permeability and decreased hypoxia.
Collagen deposition and fibrillogenesis was also decreased.
Furthermore, tumors grown in SPARC2/2 mice displayed
increased recruitment and activation of fibroblasts and alterna-
tively-activated macrophages (M2). These alterations are summa-
rized in Table 1.
Although we discovered many changes in the tumor microen-
vironment of SPARC2/2 compared to SPARC+/+ animals, the
underlying cause for increased invasion/metastasis and decreased
survival remained elusive. An initial finding was that tumors grown
in the absence of host SPARC displayed reduced deposition of the
collagen-binding proteoglycan, decorin [23], presumably due to
diminished deposition of collagen. We validated and quantified
this result with fluorescence immunohistochemistry and found that
decorin deposition in tumors grown in SPARC2/2 mice was
significantly reduced, not only within tumors, but at the tumor
capsule (Figure 1A, p=0.0051). Decorin and other ECM proteins
have been shown to bind to, contribute to the bioavailability of,
and modulate the activation of growth factors and cytokines [27].
We suspected that the diminished ECM associated with the
absence of host SPARC might enhance tumor progression by
altering growth factor localization and availability. In particular, it
is established that decorin can directly bind and regulate the
activity of TGFb [28,29,30,31]. Immunohistochemistry was
performed utilizing antibodies directed against biologically active
and total TGFb1. The results revealed that, although there was no
discernable change in total TGFb1 (Figure 1C), there was a
significant increase in active TGFb1 in tumors grown in the
absence of host SPARC (Figure 1B, p,0.0001). This was
particularly apparent in spontaneous abnormal ducts in the
Pan02 tumors. In addition, an ELISA specific for active TGFb1
was performed on SPARC+/+ and SPARC2/2 tumor lysates. By
ELISA, active TGFb1 was increased by nine-fold in tumors grown
in SPARC2/2 compared to SPARC+/+ mice (Figure 1B, bottom
center, p,0.0001).
Attenuation of TGFb1 via losartan rescues survival of
SPARC-null mice
Many of the phenotypic changes observed during tumor
progression in SPARC2/2 mice, such as enhanced vascular
permeability, increased metastasis, decreased survival and altered
immune tolerance, are consistent with elevated TGFb activity
[16,17,32,33]. To assess the significance of TGFb on the outcome
of tumor progression, we performed a survival study in which
Table 1. Pan02 Tumor-Associated Effects in SP2/2 Mice.
Tumor Growth Tumor Weight NC
Invasion & Metastasis q
Survival Q
Microvascular Properties Microvessel Density Q
Pericyte Coverage Q
Vascular Basement Membrane Density Q
Permeability q
Hypoxia Q
Extracellular Matrix Collagen Deposition Q
Collagen Fibrillogenesis Q
Decorin Content Q





Table summarizing the tumor-associated effects previously analyzed in
SPARC2/2 (SP2/2) mice bearing orthotopic Pan02 tumors. Arrows indicate
whether SPARC2/2 mice displayed an increase (q) or decrease (Q) compared
to SPARC+/+ mice. NC, no change.
doi:10.1371/journal.pone.0031384.t001
Losartan Rescues Survival of SPARC-Null Mice
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31384Figure 1. TGFb1 and the TGFb binding proteoglycan, decorin, are altered in tumors grown in the absence of stromal SPARC.
Fluorescence immunohistochemistry was utilized to quantify the amount of active and total TGFb1, as well as decorin in tumors grown in SPARC+/+
and SPARC2/2 mice (A–C). (A) Tumor sections were stained with antibody goat anti-decorin (green) and percent thresholded area quantified. DAPI
(blue) marks cell nuclei. Images were taken at the tumor edge (top panels) and the tumor center (bottom panels). Total magnification is 1006(scale
bar, 200 mM) and 2006(scale bar, 100 mM) as indicated. Dotted lines indicate the border between the tumor (T) and normal pancreas (P). (B) Tumor
sections were stained with an antibody rabbit anti-TGFa ˆ1 (green) specific for the active form and percent thresholded area quantified. DAPI (blue)
marks cell nuclei. Total magnification is 4006(scale bar, 50 mM) as indicated. Dotted lines indicate spontaneous abnormal ducts arising from the
Pan02 cells within the tumor. The amount of active TGFa ˆ1 in tumor lysates was also measured using a commercial sandwich ELISA kit (G7591
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with losartan. Losartan, an angiotensin II type 1 receptor
antagonist, is effective at inhibiting the expression and activation
of TGFb1 [25,34,35]. As previously reported, SPARC2/2 mice
succumbed to tumor burden more rapidly than their SPARC+/+
counterparts with a median survival of 28.0 days compared to 35.5
days (Figure 2A, p=0.0184) [23]. Although targeting TGFb1 with
losartan had no significant effect on survival of SPARC+/+
animals, the median survival of SPARC2/2 mice was extended
to 40.0 days by losartan therapy (Figure 2A, p=0.0129). Losartan
treatment delayed, but was unable to prevent, invasive and
metastatic progression as at the time of sacrifice every animal
exhibited extensive and aggressive tumor burden. However,
losartan therapy did reduce the splenomegaly associated with
Pan02 tumor progression (Figure 2B).
Losartan reduces invasion and metastasis in SPARC-null
mice
To assess the affect of losartan on tumor progression, local
invasion and metastasis, an endpoint study was performed;
whereby, losartan treatment was initiated the day following Pan02
tumor injection and all animals were sacrificed at four weeks,
regardless of tumor burden or health status. This endpoint study
revealed that losartan treatment was able to control local invasion
andmetastasisinSPARC+/+ and SPARC2/2 mice. Although there
were no differences in tumor/pancreas weights between genotypes
or treatment groups (data not shown), tumor growth was more
confined to the pancreas in losartan-treated groups compared to
untreated counterparts (Figure 2C). The effect of losartan on local
invasion was apparent in the SPARC2/2 mice, but not observed in
SPARC+/+ mice(Table 2).Losartan therapy reduced the number of
SPARC2/2animalswith signsoflocalinvasion(invasionincidence)
and the number of adjacent organs involved (Table 2). Local
invasion occurred predominantly in the visceral adipose, abdominal
muscle,intestine/mesenteryand spleen(Figure2D).SPARC+/+and
SPARC2/2 mice responded to losartan therapy with a reductionin
the number of animals in each group with metastatic dissemination
(metastatic incidence) and a diminution in the number of
macroscopic metastatic lesions (Table 3). Metastasis occurred
predominantly in the mesenteric lymph nodes and liver (Table 3).
Importantly, although invasion and metastatic incidence and events
were increased in SPARC2/2 compared to SPARC+/+ mice, as
previously reported [23,26], losartan normalized tumor progression
in SPARC2/2 mice to the equivalent of that observed in SPARC+/
+ counterparts (Table 2 and 3).
Therefore, local invasion and metastasis was reduced in
SPARC2/2 animals by treatment with losartan, which presumably
accounts for the survival benefit observed (Figure 2A). The fact that
levels of active TGFb are elevated in tumors grown in SPARC2/2
animals and that losartan decreases TGFb activity supports the
concept that excess TGFb1 participates in the accelerated tumor
progression and altered tumor microenvironment of orthotopic
Pan02 tumors grown in the absence of host SPARC.
Losartan reduces TGFb pathway activation in SPARC-null
mice
Although losartan, an angiotensin II type 1 receptor antagonist,
has been successfully utilized to inhibit the expression and
activation of TGFb1 in several animal models and in humans
[24,36,37,38,39], we wanted to validate that TGFb1 expression
and downstream activation of TGFb1 response genes were
effectively inhibited by losartan in our model of pancreatic cancer.
This was accomplished by performing real-time quantitative
reverse-transcriptase polymerase chain reaction (qPCR). First,
we analyzed the mRNA expression of TGFb1, TGFb2, TGFb3
and thrombospondin-1 (TSP-1). Thrombospondin-1 is a matri-
cellular protein that can function as a co-activator of latent TGFb
family members. TGFb1 and TSP-1 are induced by the activation
of angiotensin II type 1 receptor signaling and it is through
reduction in TSP-1 expression that losartan is suspected to reduce
the activation of latent TGFb1 [40,41]. Losartan decreased
TGFb1 and 3 mRNA expression in tumors from SPARC2/2
animals to levels consistent with those observed in tumors from
untreated SPARC+/+ mice, although the decrease was not
statistically significant possibly due to low sample number
(Figure 3A). TGFb2 mRNA was undetectable with the probes
used (data not shown). The expression of TSP-1 was similar
between tumors from SPARC+/+ and SPARC2/2 mice, but as
expected there was a decrease in losartan-treated compared to
untreated tumors in both genotypes (Figure 3A).
We next determined if losartan reduced TGFb1-induced gene
transcription. To broadly assess losartan effects on TGFb1
signaling, we chose to perform the commercially available RT
2
Profiler
TM PCR Array (PAMM-035; SABiosciences, Frederick,
MD). This array measures the level of mRNA of 84 TGFb
response genes. Consistent with the decrease in expression and
activation of TGFb1, many TGFb response genes revealed altered
expression (Table S1). As expected, since tumors grown in the
absence of host SPARC harbor increased active TGFb1, a
majority of TGFb target genes in tumors from SPARC2/2 mice
were elevated more than two-fold compared to tumors from
SPARC+/+ mice (Table S1, SPARC2/2 vs. SPARC+/+). Relative
to untreated counterparts, tumors grown in losartan-treated
SPARC+/+ and SPARC2/2 animals showed more than a two-
fold decrease of a majority of TGFb target genes (Table S1,
SPARC+/+ LOS vs. SPARC+/+ and SPARC2/2 LOS vs.
SPARC2/2). Most importantly, losartan treatment restored the
mRNA expression profile of tumors grown in the absence of host
SPARC to similar levels observed in untreated SPARC+/+ mice
(Figure 3B and Table S1, SPARC2/2 LOS vs. SPARC+/+).
Figure 3B shows the unsupervised hierarchical cluster analysis
performed by the online RT
2 Profiler
TM PCR Array software
provided by SABiosciences. Notice that the most closely associated
TGFb gene profiles are from tumors grown in SPARC+/+ and
losartan-treated SPARC2/2 mice (Figure 3B). As a visual, Figure
S1 shows heatmaps of the TGFb response genes listed in Table S1,
where each box represents a separate gene in the PCR array and
each map is a relative comparison between two groups. Therefore,
losartan effectively reduced the expression, activation and
signaling of TGFb1 during tumor progression in the absence of
host SPARC.
Losartan fails to restore angiogenesis and blood vessel
maturation but leads to vasoconstriction and reduced
permeability in tumors grown in SPARC-null mice
We have reported previously that tumors grown in SPARC2/2
mice demonstrated reduced microvessel density and pericyte
Promega). Data represents two independent assays that are combined by normalizing all samples to SPARC+/+ and recorded as fold change. 50 mgo f
total protein was loaded per well and samples were run in either duplicate or quadruplicate. (C) Total TGFb1 protein within tumors was assessed with
antibody rabbit anti-TGFb1,2,3 and percent thresholded area quantified. All p-values were calculated with a Student’s t-test. ns, not significant.
doi:10.1371/journal.pone.0031384.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31384Figure 2. Losartan improves survival of tumor-bearing SPARC2/2 mice. A–C) 1610
6 Pan02 cells were injected into the tail of the pancreas
of SPARC+/+ and SPARC2/2 mice. Tumors were allowed to grow for 10 days prior to initiation of losartan therapy (600 mg/L) via drinking water ad
libitum in 2% sucrose. A) Survival curve of SPARC+/+ and SPARC2/2 mice treated with losartan (LOS). The table lists the median survival and
associated p-values calculated with the Gehan-Breslow-Wilcoxon test (n=10/group). The survival curve is modified from Arnold et al 2010 [23]. B)
Graph displays spleen weight and the fold change calculated based on the weight of spleens taken from non-tumor bearing (NT) mice. Significance
was determined by a Student’s t-test and all significant p-values are indicated. C, D) 1610
6 Pan02 cells were injected into the tail of the pancreas of
SPARC+/+ and SPARC2/2 mice. Losartan therapy was given as above was initiated 24 hours after tumor cell injection and mice were sacrificed 28
days later. (C) Images of H&E stained primary tumor sections show residual pancreas and the primary tumor border of untreated and losartan-treated
(LOS) SPARC+/+ and SPARC2/2 mice. Dotted lines demarcate the normal adjacent pancreas (P) from the primary tumor (T). Total magnification (506)
and scale bars (500 mm) are indicated. (D) H&E section of a spleen displaying disruption of the splenic capsule and local tumor invasion (I). Total
magnification (2006) and scale bars (100 mm) are shown. Image of an H&E stained liver section revealing the common site for distant metastasis (M).
Total magnification (2006) and scale bars (100 mm) are indicated.
doi:10.1371/journal.pone.0031384.g002
Losartan Rescues Survival of SPARC-Null Mice
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31384recruitment, as well as increased permeability [23]. TGFb1 can
control angiogenesis, pericyte recruitment and blood vessel
function during tumorigenesis [32,42]. Therefore, we were
interested in how excess TGFb1 in the tumor microenvironment
of SPARC2/2 mice contributed to the aforementioned vascular
changes. Microvessel density and pericyte recruitment were
assessed by fluorescence immunohistochemistry. Staining with
the pan endothelial cell marker, Meca-32, validated that
microvessel density was significantly decreased in tumors grown
in SPARC2/2 mice compared to SPARC+/+ controls (Figure 4A,
p,0.0001). However, thresholded area was increased in the
absence of host SPARC and many vessels appeared dilated
(Figure 4A, p,0.0001). Therefore, the area of individual blood
vessels or mean blood vessel area was assessed. Indeed, blood
vessels were significantly larger and dilated in tumors grown in the
absence of host SPARC accounting for the increase in thresholded
area despite a decrease in microvessel density (Figure 4A,
p,0.0001). Losartan treatment significantly reduced microvessel
density in tumors from SPARC+/+ mice (p=0.0473) but did not
affect microvessel density of tumors from SPARC2/2 mice
(Figure 4A). On the other hand, losartan significantly reduced the
mean blood vessel area in tumors grown in the absence of host
SPARC, essentially restoring blood vessel size to that found in
tumors from SPARC+/+ animals (Figure 4A, p,0.0001). There-
fore, losartan treatment decreased microvessel density in tumors
grown in SPARC+/+ mice and constricted blood vessels in tumors
from SPARC2/2 mice.
Colocalization of Meca-32 and a pericyte marker, NG2,
confirmed that pericyte recruitment was significantly diminished
in tumors grown in SPARC2/2 mice compared to SPARC+/+
controls (Figure 4B, p=0.0173). However, losartan therapy did
not enhance pericyte coverage in tumors from SPARC2/2 or
SPARC+/+ mice. In fact, although not significant, losartan further
reduced pericyte recruitment in tumors grown in SPARC2/2 and
SPARC+/+ mice. This is explained in part by the observation that
losartan can inhibit pericyte migration [43].
In addition to alterations in microvessel density and maturity,
tumors grown in SPARC2/2 mice exhibited enhanced vascular
permeability relative to tumors from SPARC+/+ controls [23]. The
permeability of fluorescein isothiocyanate-labeled dextran (FITC-
Dextran) (2610
6 kDa) was determined for tumors grown in mice
treated with losartan (Figure 4C). This experiment validated that
tumors grown in the absence of host SPARC display increases in
permeability to macromolecules (Figure 4C, p=0.0834). More
importantly, losartan treatment abrogated the increase in FITC-
Dextran in tumors grown in SPARC2/2 mice and restored
permeability to levels equivalent to that observed in tumors grown
in untreated SPARC+/+ mice (Figure 4C, p=0.0249).
Therefore, blockade of aberrant TGFb1 activity with losartan in
tumors grown in the absence of host SPARC reduces vasodilation
and blood vessel permeability, but does not restore microvessel
density.
Collagen deposition and fibrillogenesis in tumors grown
in SPARC-null mice is reduced by losartan
Previous studies have shown that tumors grown in SPARC2/2
mice have reduced collagen deposition and fibrillogenesis
[23,26,44]. Although this was a consistent observation, the question
still remained as to whether alterations in the collagen matrix
influenced metastasis and/or survival of SPARC2/2 mice bearing
orthotopic Pan02 tumors. Due to the fact that losartan treatment
improved survival and reduced metastasis in SPARC2/2 mice, the




SPARC+/+ 10 8 (80%)
SPARC+/+ LOS 8 8 (100%)
SPARC2/2 8 8 (100%)
SPARC2/2 LOS 8 4 (50%)
Animals bearing orthotopic Pan02 tumors were treated with losartan as
described in the methods. Local invasion was defined as tumor growth into
adjacent organs with attachment to the primary tumor as determined by
necropsy. Invasion incidence was defined as the number of animals in each
group with signs of local invasion.
doi:10.1371/journal.pone.0031384.t002
Table 3. The effect of losartan on Pan02 metastasis.
Metastatic Incidence
Group n= Lung Kidney Liver Spleen Diaphragm Intestine I.P. Other Total
SPARC+/+ 10 0 0 1 (10%) 0 2 (20%) 6 (60%) 4 (40%) 1 (10%) 7 (70%)
SPARC+/+ LOS 8 0 0 0 1 (13%) 0 2 (25%) 2 (25%) 1 (13%) 4 (50%)
SPARC2/2 8 0 0 1 (13%) 1 (13%) 0 7 (88%) 0 1 (13%) 8 (100%)
SPARC2/2 LOS 8 0 1 (13%) 0 0 0 6 (75%) 1 (13%) 0 6 (75%)
Total Metastatic Events
Group n= Lung Kidney Liver Spleen Diaphragm Intestine I.P. Other Total Mean
SPARC+/+ 1 0 0 0102 1 5622 6 2 . 6 0
SPARC+/+ L O S 8 0 0010 4 218 1 . 0 0
SPARC2/2 8 0 0220 2 3012 8 3 . 5 0
SPARC2/2 L O S 8 0 1000 1 0301 4 1 . 7 5
Mice bearing orthotopic Pan02 tumors were treated with losartan (600 mg/L). Therapy began immediately psot tumor cell injection and tumor burden was assessed 28
days later. Metastatic incidence was recorded as the number of mice bearing metastases in each organ listed in each treatment group. Total metastatic events/organ/
group are also shown.
doi:10.1371/journal.pone.0031384.t003
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proper collagen deposition and maturation. Masson’s trichrome
staining confirmed that tumors grown in the absence of host
SPARC display reduced collagen deposition (data not shown).
However, losartan treatment failed to restore collagen deposition in
tumors grown in SPARC2/2 mice (data not shown). Furthermore,
the amount of collagen production was unaffected by either
genotype or losartan therapy as measured by hydroxyproline
analysis (Figure 5A). When collagen deposition and maturation in
orthotopic Pan02 tumors was quantified by second harmonic
generation (SHG), it was found that collagen deposition and
maturation decreased in tumors grown in the absence of host
SPARC and that losartan augmented this effect resulting in an even
further decrease in collagen deposition and maturation (Figure 5B).
The deposition of immature (red), mature (green) and total collagen
(both) were all significantly reduced in losartan-treated compared to
untreated SPARC2/2 mice (Figure 5B, p=0.0053, p=0.0001,
p=0.0002, respectively).
Losartan fails to reduce the infiltration of alternatively-
activated macrophages or myeloid derived suppressor
cells
Previously, we identified that tumors grown in the absence of
host SPARC exhibited an increase in macrophage recruitment
and, more specifically, an increase in alternatively-activated
macrophages (M2) [23]. Based on this result we hypothesized
that the tumor microenvironment in SPARC2/2 mice was
‘‘immune tolerant’’, which could facilitate metastasis. As a result,
we assessed macrophage recruitment and activation after losartan
treatment. Immunohistochemistry for classically activated macro-
phages (M1) using iNos and M2 macrophages using CD163 and
the mouse mannose receptor (MMR) validated that the ratio of
M2 to M1 macrophage in tumors grown in the absence of host
SPARC was significantly increased relative to those grown in
SPARC+/+ controls (Figure 6A, p=0.0321). However, losartan
therapy did not reduce the number of M2 macrophages in either
genotype (Figure 6A). In fact, tumors grown in losartan-treated
mice exhibited an even larger increase in the ratio of M2 to M1
macrophage (Figure 6A, SPARC+/+ vs. SPARC+/+ LOS,
p=0.0576; SPARC2/2 vs. SPARC2/2 LOS, p=0.0040).
Myeloid-derived suppressor cells (MDSCs) have also been
shown to activate tumor-associated immune tolerance [45].
Therefore, we performed fluorescence immunohistochemistry
with antibodies targeting CD11b and GR-1, two markers that
when colocalized serve to identify the MDSC population.
Quantification of the number of CD11b
+GR-1
+ cells in tumor
sections revealed that neither genotype nor losartan treatment
significantly altered the recruitment of MDSCs (Figure 6B).
Therefore, losartan restores survival and diminishes metastasis
without reducing the infiltration of M2 macrophage and MDSC,
cell populations known to participate in immunosuppression.
Losartan reduces the activation of regulatory T-cells in
tumors and spleens of SPARC-null mice
A third population of immune cells implicated in immune
tolerance are regulatory T-cells (Tregs) [46,47,48]. Tregs had not
been assessed previously in this orthotopic model. Therefore, we
performed fluorescence immunohistochemistry to assess the
recruitment of activated and regulatory T-cells. Co-staining with
the general T-cell marker, CD3, and the activated T-cell marker,
CD69, allowed the quantification of percent activated T-cells or
the number of CD3+CD69+ double positive cells divided by the
total number of CD3+ cells. In general, the percent activated T-
cells was not significantly different between the groups, although
there was a marked trend towards decreased activated T-cells in
tumors grown in the absence of host SPARC, regardless of
losartan treatment (Figure 7A, p=0.0507). On the other hand, the
percent Tregs, assessed by colocalization of CD25 and foxp3, was
Figure 3. Losartan reduces TGFb-induced gene expression in tumors from SPARC2/2 mice. (A) The mRNA expression of TGFb1, TGFb3
and TSP-1 in tumors from SPARC+/+ and SPARC2/2 mice treated with losartan was assessed with taqman-based qPCR. n=3/group and p-values
were calculated with the Student’s t-test. (B) Clustergram results from the RT
2 Profiler
TM PCR Array (PAMM-035; SABiosciences). Green indicates
negative fold-regulation, whereas red indicates positive fold-regulation relative to six internal control genes.
doi:10.1371/journal.pone.0031384.g003
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31384significantlyincreasedintumorsgrown inSPARC2/2 comparedto
SPARC+/+mice(Figure7B,p,0.0001).Moreimportantly,losartan
treatment abrogated the increase of Tregs (Figure 7B, p=0.0003).
Since T-cell mediated immunosuppression is dependent on the
balance between activated and regulatory T-cells, the ratio of
regulatory CD25+foxp3+ T-cells to activated CD3+CD69+ T-cells
was calculated (Figure 7C). Identical to the results for the percent
Tregs, tumors from SPARC2/2 mice had an increase in the ratio
of regulatory T-cells to activated T-cells relative to those from
SPARC+/+ mice and losartan therapy was able to neutralize this
effect (Figure 7C, SPARC+/+ vs. SPARC2/2,p ,0.0001;
SPARC2/2 vs. SPARC2/2 LOS, p,0.0001). T-cell recruitment
and mobilization to the spleen was also determined (Figure 7D).
Losartan treatment reduced the number of CD3+CD69+ double
positive activated T-cells mobilized to the spleen in SPARC2/2
mice (Figure 7D, p=0.0017). In addition, although there were no
changes in Treg recruitment to the spleens of SPARC2/2
compared to SPARC+/+ mice, losartan therapy significantly
reduced the number of CD25+foxp3+ double positive Treg in both
genotypes (Figure 7D, SPARC+/+ vs. SPARC+/+ LOS, p=0.0042;
SPARC2/2 vs. SPARC2/2 LOS, p=0.0401).
Therefore, tumors grown in the absence of host SPARC display
enhanced activation and recruitment of Tregs compared to those
from SPARC+/+ mice. Furthermore, losartan therapy was able to
abrogate this increase and reduce the recruitment and mobiliza-
tion of Tregs to the tumor and spleen. As a result, it is possible that
losartan reduced metastasis and rescued survival of SPARC2/2
mice by rebalancing immunosuppression within the tumor
microenvironment.
Pan02 cells in vitro and in vivo are undergoing epithelial-
to-mesenchymal transition
An observation was made in vitro and in vivo that Pan02 cells
exhibit many mesenchymal characteristics such as an elongated
cell shape in culture with no signs of a cobblestone pattern
characteristic of epithelial monolayers. This is important because
TGFb1 has been shown to have a dichotomous effect on tumor
cell proliferation and migration depending on the epithelial versus
mesenchymal nature of the cell [49]. Not only does TGFb1 induce
epithelial to mesenchymal transition (EMT) but, once a cell is
mesenchymal, it no longer responds to TGFb1 with immobility
and quiescence [49,50]. Instead, TGFb1 induces the migration
and proliferation of mesenchymal-like fibroblastoid tumor cells
[49]. To determine if Pan02 cells have undergone EMT, we
stained tumor sections with E-cadherin, an epithelial marker, and
vimentin, a mesenchymal marker. The majority of the Pan02
tumors were negative for E-cadherin; however, spontaneous de novo
ducts derived from Pan02 cells displayed robust E-cadherin
expression (Figure S2A). These ducts, while abnormal, expressed
E-cadherin that was appropriately localized to cell-cell junctions
(Figure S2A, Zoom). This suggests that Pan02 cells are in the
process of undergoing EMT, but still possess the ability to return to
an epithelial-like state. Furthermore, Pan02 tumors displayed high
expression of vimentin, which confirms that Pan02 cells display a
mesenchymal-like phenotype (Figure S2B). As additional evidence,
immunocytochemistry of Pan02 cells in vitro, reveals that b–catenin
is localized to the nucleus (Figure S2C).
Therefore, the fact that Pan02 cells have undergone or are in
the process of EMT, suggests that the excess TGFb1 during tumor
progression in SPARC2/2 mice might directly stimulate their
migration and subsequent metastasis.
SPARC and TGFb1 enhance Pan02 cell migration
To determine if Pan02 cell migration is influenced by SPARC
and/or TGFb1, in vitro scratch/wound assays were performed.
Pan02 cells were treated with 0.1% FBS alone or in combination
with recombinant SPARC (10 mg/ml), recombinant TGFb1
(250 ng/ml), SPARC and TGFb1, or anti-TGFb1,2,3 (10 mg/
ml). Wound width was measured six hours after wound initiation.
Pan02 cells treated with SPARC or TGFb1 exhibited a significant
increase in wound closure or decrease in wound width relative to
0.1% FBS alone (Figure 8A, both p,0.0001). Furthermore, the
combination of SPARC and TGFb1 significantly accelerated
wound closure compared to either treatment alone (Figure 8A,
SPARC vs. SPARC+TGFb1p ,0.0001; TGFb1 vs. SPARC+
TGFb1 p=0.0002). Lastly, neutralizing TGFb signaling with an
anti-TGFb1,2,3 antibody significantly delayed wound closure
compared to 0.1% FBS alone (Figure 8A, p=0.0028). It is
important to note that Pan02 cells express and secrete measurable
amounts of SPARC (Figure 8A, top right panel). Therefore, if
SPARC and TGFb1 act concurrently to enhance Pan02 cell
migration, then the secretion of SPARC by Pan02 cells in vivo may
enhance the pro-migratory effects of excess TGFb1. To validate
that SPARC and TGFb1 induce the migration of Pan02 cells,
transwell migration assays were utilized. Pan02 cells migrated
towards 0.5% FBS and were treated with recombinant SPARC
(10 and 30 mg/ml), recombinant TGFb1 (50, 250 and 500 ng/ml)
or SPARC (10 mg/ml) in combination with anti-TGFb1,2,3
(10 mg/ml). TGFb1 dose-dependently enhanced Pan02 migration
(Figure 8B, left graph). Likewise, SPARC also dose-dependently
increased Pan02 migration (Figure 8B, right graph). Moreover,
SPARC-induced migration was dependent on TGFb1 because
addition of the anti-TGFb1,2,3 completely abrogated the effect of
SPARC on migration (Figure 8B, right graph, SPARC (10 mg/ml)
vs. SPARC (10 mg/ml)+anti-TGFb1,2,3 p,0.0001).
Therefore, Pan02 migration is enhanced by SPARC and
TGFb1, whereby SPARC-induced migration is dependent on
TGFb1. This data provides plausible evidence that TGFb1 in the
tumor microenvironment is directly regulating the migration of
Pan02 cells and stimulating their dissemination.
Discussion
Our results provide evidence that enhanced metastasis and
decreased survival of tumor bearing SPARC-deficient mice is a result
Figure 4. Losartan decreases vessel sizebut noteffect microvessel density or pericyte recruitmentin Pan02 tumors grown in SPARC2/2
animals. Fluorescence immunohistochemistry was utilized to quantify microvessel density and pericyte recruitment in Pan02 orthotopic tumors
grown in SPARC+/+ and SPARC2/2 mice treated with losartan (A–B). (A) Tumor sections were stained with rat anti-mouse endothelial cell Meca-32
(red) [64]. DAPI (blue) marks cell nuclei. The percent thresholded area normalized to untreated SPARC+/+, number of blood vessels and mean blood
vessel area were quantified. Total magnification (2006) and scale bars (100 mm) are indicated. (B) Sections were stained with Meca-32 and rabbit anti-
NG2. Percent mature vessels were calculated as the number of Meca-32 & NG2 colocalized vessels divided by the total number of Meca-32 positive
vessels. Total magnification (1006) and scale bars (200 mm) are shown. C) SPARC+/+ and SPARC2/2 mice bearing orthotopic Pan02 tumors and
treated with losartan were injected intravenously with fluorescein isothiocyanate-conjugated dextran (FITC-Dextran) (25 mg/ml) (2610
6 mw; D7137;
Molecular Probes/Invitrogen) in 0.9% sterile saline at a dose of 200 ml/mouse. The fluorescent dextran was allowed to circulate 10 minutes before the
mice were euthanized. Tissue was snap-frozen, sectioned (10 mm) and immediately analyzed by fluorescence microscopy. Percent thresholded area
was quantified. Total magnification (2006) and scale bars (100 mm) are indicated. All p-values were calculated with the Student’s t test.
doi:10.1371/journal.pone.0031384.g004
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31384of aberrant activation of TGFb1. Inhibition of the expression and
activation of TGFb1 with the angiotensin II type 1 receptor
antagonist, losartan, rescued survival of SPARC2/2 mice
challenged with Pan02 orthotopic tumors. It is likely that median
survival of SPARC2/2 mice was extended because local invasion
and metastatic burden was reduced by losartan treatment.
Previously identified alterations in the tumor microenvironment
between SPARC+/+ and SPARC2/2 mice were reassessed after
losartan therapy. We found that vasodilation and blood vessel
permeability are influenced by excess active TGFb1 detected in
tumors grown in the absence of host SPARC and, therefore, may
contribute to metastasis and survival. On the other hand,
Figure 5. Losartan effect on collagen deposition and maturation. The amount of collagen production, deposition and maturation was
assessed in Pan02 orthotopic tumors grown in SPARC+/+ and SPARC2/2 mice treated with losartan. (A) The amount of collagen produced and
secreted within tumors was quantified by hydroxyproline analysis. (B) Collagen content and maturity was quantified by second harmonic generation
(SHG). Frozen tumor sections (50 mm) were mounted in PBS. Collagen fibers within the tumor sections were excited at 900 nm to generate a SHG
signal which was then detected at 450 nm. Both forward scattered signal, indicative of mature collagen (green) and backward scattered signal,
indicative of immature collagen (red) was detected. Percent thresholded area of immature, mature and total collagen was quantified. Total
magnification (4006) and scale bars (50 mm) are indicated. All p-values were calculated with the Student’s t test.
doi:10.1371/journal.pone.0031384.g005
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31384decreased microvessel density and pericyte recruitment were not
restored with losartan treatment. This is not altogether unexpected
given the fact that the angiotensin system directly impacts vascular
cells. Furthermore, considering that SPARC is required for proper
collagen deposition and fibrillogenesis, it is not surprising losartan
was unable to restore collagen deposition in tumors grown in the
absence of host SPARC. In fact, the inhibition of TGFb1 with
losartan led to a further decrease in collagen deposition and
maturation in tumors from SPARC2/2 mice. We previously
found that macrophage levels were enhanced in Pan02 tumors
grown in SPARC2/2 mice [23]. Losartan, which has been shown
to inhibit inflammatory signaling in macrophages [51] promoted
Figure 6. Losartan does not decrease macrophage and MDSC infiltration. Fluorescence immunohistochemistry was utilized to assess
macrophage and myeloid derived suppressor cell (MDSC) recruitment in tumors grown in Pan02 orthotopic tumors grown in SPARC+/+ and SPARC2/2
mice treated with losartan (A–B). (A) Frozen tumor sections were stained with either antibody rabbit anti inos (red) for detection of M1 macrophage or
antibody rabbit anti CD163 (red) and antibody rat anti MMR (green) for detection of M2 macrophage. DAPI (blue) marks cell nuclei. The number of inos
positive cells and the number of CD163 and MMR double positive cells was counted and the ratio of M2 to M1 calculated. Total magnification (2006,
4006) and scale bars (100 mm, 200 mm) are indicated. (B) Frozen tumor sections were stained with antibodies FITC-conjugated rat anti CD11b (green)
and CY3-conjugated rat anti GR-1 (red). DAPI (blue) marks cell nuclei. The number of CD11b and GR-1 double positive cells was counted. Total
magnification (4006) and scale bars (200 mm) are indicated. All p-values were calculated with the Student’s t test.
doi:10.1371/journal.pone.0031384.g006
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PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e31384an increase in the M2:M1 macrophage ratio in tumors grown in
SPARC-deficient animals. Losartan treatment did however,
negate the increase in Treg recruitment observed in tumors
grown in the absence of host SPARC. This is likely due to
inhibition of TGFb, which in the tumor microenvironment
promotes conversion of T cells to Treg cells [52]. Furthermore,
Zhong et al [53] found that inhibition of TGFbR2 resulted in
attenuation of TGFb-mediated induction of Tregs and Treg
mediated suppression of T-cell activation. Tregs contribute to
tumor immune tolerance by neutralizing inflammatory responses
and have been shown to correlate with worse clinical outcomes
[48]. Thus, an imbalance in immunosuppressive and inflamma-
Figure 8. SPARC and TGFb1 promote Pan02 migration. The ability of SPARC and TGFb1 to control Pan02 cell migration in vitro was assessed.
(A) A wound-healing assay was utilized to determine if SPARC and TGFb1 could act concomitantly to enhance Pan02 migration. Cells were plated at a
density of 1.5610
5 cells per well in 96-well plates and allowed to grow to 100% confluency. A scratch was made and cells allowed to migrate into the
wound. Recombinant SPARC (10 mg/ml), recombinant TGFb1 (250 ng/ml) and anti-TGFb1,2,3 (10 mg/ml) were prepared in DMEM 0.1% FBS. The
wound width (mm) was measured after 6 hours. Inset of immunocytochemistry with antibody goat anti-mouse SPARC reveals that Pan02 cells do
express SPARC. (B) A transwell migration assay was performed as an additional means to assess SPARC and TGFb1 effect on Pan02 migration, as well
as, to determine if SPARC effect on Pan02 migration is TGFb dependent. Cells were serum-starved overnight then seeded at 20,000 cells per 24-well
0.8 mm cell culture insert (BD Falcon). DMEM 0.1% FBS served as the chemoattractant. Recombinant SPARC (10 and 30 mg/ml) was added to the
upper chamber, while recombinant TGFb1 (50, 250 and 500 ng/ml) and anti-TGFb1,2,3 (5 mg/ml) were added to the bottom chamber. Cells were
allowed to migrate 24 hours at 37uCi n5 %C O 2. Migrated cells were fixed, stained and counted. Cell counts were normalized to DMEM 0.1% FBS and
recorded as % migrating cells. ns, not significant. All p-values were calculated with the Student’s t test.
doi:10.1371/journal.pone.0031384.g008
Figure 7. Losartan reduces Treg levels in Pan02 tumors grown in SPARC2/2 mice. Fluorescence immunohistochemistry was utilized to
assess the recruitment of activated and regulatory T-cells in Pan02 orthotopic tumors (A–C) or spleens (D) in SPARC+/+ and SPARC2/2 mice treated
with losartan. (A) Frozen tumor sections were stained with antibody rat anti-CD3 (red) and hamster anti-CD69 (green) for detection of activated T-
cells. DAPI (blue) marks cell nuclei. Percent activated T-cells was calculated by dividing the number of CD3 and CD69 double positive cells by the total
number of CD3 positive cells. Total magnification (4006) and scale bars (200 mm) are indicated. (B) Frozen tumor sections were stained with rat anti-
foxp3 (red) and rat anti-CD25 (green) for detection of regulatory T-cells. DAPI (blue) marks cell nuclei. Percent regulatory T-cells was calculated by
dividing the number of foxp3 and CD25 double positive cells by the total number of CD3 positive cells. Total magnification (4006) and scale bars
(200 mm) are indicated. (C) The ratio of regulatory T-cells to activated T-cells was calculated by dividing the number of CD3 and CD69 double positive
cells by the number of foxp3 and CD25 double positive cells. Data was recorded as percent. (D) Frozen splenic sections were stained for activated and
regulatory T-cells as described in A and B. The number of activated and regulatory T-cells was counted. ns, not significant. All p-values were
calculated with the Student’s t test.
doi:10.1371/journal.pone.0031384.g007
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and decreased survival of SPARC2/2 mice.
Losartan treatment had no effect on survival of wild-type mice
bearing Pan02 tumors. Other reports suggest that losartan can
slow the growth of Pan02 tumors and when used in combination
with gemcitabine can result in potent inhibition of tumor growth
[54]. Furthermore, Diop-Frimpong et al. [55] report that inhibition
of collagen synthesis with losartan improves delivery of therapeutic
nanoparticles. Neither of these reports document whether the anti-
tumor mechanism of action of losartan is dependent upon
inhibition of angiotensin II, rather both are consistent with an
anti-TGFb action of the drug. A confounding result is the slight
increase in local invasion in wild-type mice treated with losartan
(Table 2). The mechanisms underlying this are unclear; however,
losartan therapy increased the M2:M1 macrophage ratio in
tumors grown in wild-type mice and M2 macrophages are known
to promote tumor progression. Another intriguing possibility is
that the increase in local invasion is a response to the anti-
angiogenic activity of losartan. Inhibition of angiogenesis has been
shown in some systems, including models of pancreatic cancer, to
increase local invasion [56].
Although losartan was able to effectively reduce the expression,
activation and signaling of TGFb1, further validation is needed to
prove that it is through the inhibition of TGFb1 and not
angiotensin II that tumor progression is reduced in SPARC2/2
mice. Direct inhibition of TGFb1 could be achieved with
neutralizing antibodies to TGFb1 or TGFbR2, [53,57,58] or
small molecular weight inhibitors [59]. Survival, invasion,
metastatic burden, vasodilation, blood vessel permeability and
the immune profile would need to be reevaluated after treatment
with a more selective TGFb inhibitor and compared to the results
of the losartan studies. LY2109761 has shown efficacy in murine
models of pancreatic cancer [60]; however, to date antibody based
strategies to inhibit TGFb in pancreatic cancer have not been
communicated.
It is clear that TGFb1 is an important regulator of metastasis
and survival in SPARC2/2 mice bearing orthotopic pancreatic
tumors. What is not completely clear is how losartan reduces
metastasis and rescues survival of mice lacking SPARC. Several
possibilities exist, including ‘‘normalization’’ of the vasculature by
constricting the blood vessels and reducing permeability, as well as
rebalancing the immune compartment by reducing regulatory T-
cells. These effects could be mediated by inhibition of TGFb.
Another major possibility is that TGFb1 is directly affecting the
migration and dissemination of Pan02 cells and this is inhibited by
losartan. At this point, we can only speculate as to why TGFb1i s
activated aberrantly in the absence of stromal SPARC. We
hypothesize that alterations in the ECM such as decreased
collagen deposition and reduced decorin, increase the bioavailable
pool of latent TGFb1, leaving more to bind and get activated at
the cell surface. We have reported recently that SPARC can
reduce TGFb activity on the surface of pericytes [14]; we are
investigating whether an analogous system is also in place on
tumor cells. Expression of SPARC in human pancreatic
adenocarcinoma is often lost due to promoter hypermethylation
[61] and this correlates with the switch in TGFb from a tumor
suppressor to tumor promoter. It is therefore tempting to speculate
based on the present results and our studies in SPARC-deficient
animals [14,23,26] that SPARC is a central control point for
regulation of TGFb activity in the tumor microenvironment.
Finally, therapy that includes losartan in pancreatic cancer
patients that have lost tumor cell expression of SPARC is a
potential strategy to control TGFb-mediated tumor progression.
Materials and Methods
Tissue Culture
The murine pancreatic adenocarcinoma cell line (Pan02, also
known as Panc02) was purchased from the Developmental
Therapeutics Program, Division of Cancer Treatment and
Diagnosis, National Cancer Institute (Frederick, MD), and grown
in high glucose Dulbecco’s Modified Eagles Medium (DMEM+-
GlutaMAX
TM-1, Invitrogen, Carlsbad, CA) supplemented with
5% fetal bovine serum (FBS, Life Technologies, Grand Island,
NY). The Pan02 cell line was tested (Impact III PCR profiles; MU
Research Animal Diagnostic Laboratory, Columbia, MO) and was
found to be pathogen-free.
Orthotopic Tumor Model
B6;129S-Sparc
tm1Hwe mice were generated as described previ-
ously [62] and backcrossed into C57BL/6J a minimum of 10
generations. The mice were housed in a pathogen-free facility and
experiments were conducted under a protocol (APN 0974-06-01-1)
approved by the Institutional Animal Care and Use Committee of
UT Southwestern Medical Center (Dallas, TX). All experiments
were performed with Sparc-null (SPARC2/2)a n dwild-type
(SPARC+/+) littermates. For injections, confluent cultures of
Pan02 cells (.90% viable) were trypsinized, pelleted in DMEM
5% FBS, washed twice in phosphate buffered saline (PBS) and
resuspended in 0.9% sterile saline (Sigma, St. Louis, MO). Tumor
cells (1610
6) were injected directly into the tail of the pancreas to
establish orthotopic tumors as previously described [26,63]. For the
survival study, individual mice were monitored daily and were
euthanized whentheydisplayedsignsoftumor-associated morbidity
such as excessive weight gain or loss, ascites, lethargy and/or
distress. Bulk tumor growth was monitored through abdominal
palpation. For the endpoint study, the entire cohort of mice was
euthanized four weeks after tumor cell injection. The liver, heart,
lung, kidney, brain, spleen and pancreas, including the tumor, were
removed and weighed. Tumor could not be separated from the
pancreas so tumor weights include residual pancreas. Metastasis
and local invasion into surrounding organs was assessed macro-
scopically by visual examination. Suspected metastases were fixed,
stained with H&E and verified as metastatic lesions histologically.
Therefore, only visible macroscopic metastatic and locally invasive
lesions were counted towards incidence and burden.
TGFb Inhibition with losartan, an Angiotensin II Type 1
Receptor Antagonist
Animals bearing orthotopic Pan02 tumors were treated with the
angiotensin II type 1 receptor antagonist, losartan potassium
(Cozaar, Merck, Whitehouse Station, NJ), shown to also inhibit
the expression and activation of TGFb. Therapy was given via
drinking water ad libitum at a dose of 600 mg/L in 2% sucrose
solution. The drinking solution was changed 3 times a week.
Animals were randomized into treatment groups matched for age
and sex. For the survival study, therapy began 10 days after tumor
cell injection and continued the entire duration of the experiment.
Therapy began immediately for the endpoint study and continued
for 4 weeks until the entire group was sacrificed. Local invasion
was defined as tumor growth into surrounding organs that
remained attached to the primary tumor, while a nodule was
considered a metastasis if it was located in a distant organ or
clearly had no connection to the primary tumor.
Immunohistochemistry
Fixed Tissue. Tissues were fixed in Methyl Carnoy’s solution
(60% methanol, 30% chloroform, 10% glacial acetic acid) and sent
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Medical Center (Dallas, TX) for paraffin-embedding and
sectioning. The Molecular Histopathology Laboratory also
performed staining with hematoxylin & eosin or Masson’s
trichrome. Tissue sections were deparaffinized and rehydrated in
PBS containing 0.2% Tween-20 (PBSt) prior to staining.
Frozen Tissue. Tissues were snap-frozen in liquid nitrogen,
embedded in optimal cutting temperature compound (OCT)
(Tissue-TekH), cut into 10 mm thick sections, air-dried overnight,
fixed for 2 minutes in acetone and washed in PBSt prior to
staining.
Fluorescence Detection. Deparaffinized and rehydrated
sections were blocked in 20% AquaBlock (East Coast Biologics),
incubated with primary antibody overnight at 40uC, incubated
with fluorophore-conjugated (FITC or Cy3) secondary antibody
(Jackson Immunoresearch) (1:500) for 1–2 hours at room
temperature and mounted with ProLong Gold Antifade Reagent
with DAPI (Invitrogen).
Antibody Specifics. Primary antibodies used for IHC are
listed in Supplemental Table S2. Antigen retrieval was performed,
where indicated, by digesting with 20 mg/ml proteinase K for
5 minutes at room temperature.
Imaging and Quantification
Tissue sections were analyzed with a Nikon Eclipse E600
microscope (Nikon, Lewisville, TX). Color images were captured
with a Nikon Digital Dx1200me camera and Act1 software
(Universal Imaging Corporation, Downington, PA). Fluorescence
images were captured with a Photometric Coolsnap HQ camera
and were captured randomly throughout the entire tumor,
including the center and border, and under identical conditions
including magnification and exposure time to allow quantification
of signal intensities, object counts, percent thresholded area and
colocalization with NIS Elements AR 2.30 software (Nikon).
Images were thresholded to exclude background signal from
secondary antibody alone. An average of ten images per tumor
and a minimum of three tumors per group were used for each
target.
TGFb1 enzyme-linked immunosorbent assay (ELISA)
Tumors were homogenized in lysis buffer (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1% Triton X-100) containing proteinase
inhibitors (Complete Proteinase Inhibitor Cocktail Tablets, Roche,
Indianapolis. IN). Tissue debris was pelleted and the resulting
supernatant was used in subsequent analysis. Total protein was
determined with a BCA protein assay (Pierce, Rockford, IL). An
ELISA for active TGFb1 (TGF beta 1 Emax ImmunoAssay
System, Promega, Madison, WI) was performed on 50 mg of total
protein per well according to the manufacturer’s protocol. A
minimum of 4 tumors per group was analyzed in duplicate. Data
were normalized to SPARC+/+.
Real-Time Quantitative Reverse-Transcriptase Polymerase
Chain Reaction (qPCR)
RNA Isolation and Purification. RNA was isolated from
tumors collected in the survival study utilizing TRIzolH
(Invitrogen) reagent according to the manufacturer’s protocol.
Four milliliters of TRIzolH was used to isolate RNA from 100 mg
of tumor. RNAse inhibitor (Roche) was then added to the isolated
RNA and treated with DNAse (DNA Free Kit; Ambion, Austin,
TX). The RNA was then further purified with the RNeasy Mini
Kit (Qiagen, Valencia, CA). The samples were then eluted in
RNAse/DNAse free water and utilized for subsequent cDNA
synthesis.
Standard qPCR. Purified RNA, three samples per group,
was reverse transcribed into cDNA using the iScript
TM cDNA
synthesis kit (Bio-Rad, Hercules, CA). Taqman probes for mouse
GAPDH, transforming growth factor beta 1 (TGFb1),
transforming growth factor beta 3 (TGFb3) and
thrombospondin-1 (TSP-1) were purchased from Applied
Biosystems (Foster City, CA). Real-time qPCR was performed
with iTaq
TM Supermix with ROX (Bio-Rad). The fold change was
calculated as 2
2DCT where CT is the cycle threshold and DCT is
the difference between the CT of the desired probe and the CT of
GAPDH. Fold changes were then normalized to the SPARC+/+
group for each probe.
TGFb qPCR Array. The expression of 84 genes related to the
TGFb signaling pathway was assessed with the RT
2 Profiler
TM
PCR Array (PAMM-035; SABiosciences, Frederick, MD).
Synthesis of cDNA and real-time PCR was performed according
to the manufacturer’s protocol using the RT
2 First Strand Kit
(SABiosciences) and RT
2 qPCR Master Mix (SABiosciences).
Three RNA samples were pooled for each group prior to cDNA
synthesis. Therefore, only one array was performed for each
group. Cycle thresholds (CT) were uploaded to SABiosciences’
online PCR array data analysis software allowing for the
calculation of fold change/regulation and production of the
clustergram and heatmaps. http://www.sabiosciences.com/pcr/
arrayanalysis.php
Fluorescent Dextran Permeability
Prior to sacrifice, mice were injected intravenously (tail vein)
with fluorescein isothiocyanate-conjugated dextran (FITC-Dex-
tran) (25 mg/ml) (2610
6 mw; D7137; Molecular Probes/Invitro-
gen, Eugene, OR) in 0.9% sterile saline at a dose of 200 ml/mouse.
The fluorescent dextran was allowed to circulate 10 minutes
before the mice were euthanized. Organs were removed, weighed,
snap frozen, embedded in OCT and cut into 10 mm thick sections.
FITC-dextran permeability was immediately assessed by fluores-
cence microscopy. A minimum of ten random photographs was
taken of each tumor section, with an average of three animals per
group. Results were recorded as mean percent thresholded area.
Hydroxyproline Analysis
Mice were anesthetized with isoflurane and organs were
removed and weighed as described before. Organs were then
snap frozen, lyophilized, weighed (dry weight), pulverized and
subjected to complete acid hydrolysis with 6 N HCl for 18 hours
at 120uC. Each sample was then neutralized to pH 7 with 4 N
NaOH. Chloramine T (1 ml) was added to 2 ml volumes of
collagen sample and incubated at room temperature for
20 minutes. Ehrlich’s Reagent (1 ml) (60% perchloric acid,
15 ml 1-propanol, 3.75 g p-dimethyl-amino-benzaldehyde in
25 ml) was added and samples were incubated at 60uC for
20 minutes. Absorbance at 558 l was read on a spectrophotom-
eter. Collagen was quantified as mg hydroxyproline per mg dry
weight of starting material.
Second Harmonic Generation Collagen Quantification
Frozen tumor sections (50 mm) were mounted in PBS and
coverslipped. A Zeiss LSM510 META NLO using an Achroplan
406/0.8 W objective lens (Zeiss, Roslyn, New York) was used to
visualize the tissue sections. Collagen fibers within the tumor
sections were excited at 900 nm with a Chameleon XR pulsed
Ti:sapphire laser (Coherent, California) to generate a second
harmonic generation (SHG) signal which was then detected at
450 nm. Excitation light was removed by a HQ 450 sp-2p filter
(Chroma Technology, Vermont) and forward scattered signal,
Losartan Rescues Survival of SPARC-Null Mice
PLoS ONE | www.plosone.org 15 February 2012 | Volume 7 | Issue 2 | e31384indicative of mature collagen, was detected with the transmitted
light detector. A 680 nm short-pass dichroic mirror was utilized to
remove backscattered excitation light. Backward scattered signal,
indicative of immature collagen, was detected with a non-
descanned detector placed at the illumination port of the wide-
field epifluorescence light path. Two z-stack (10-step) images, at
the areas of greatest collagen deposition, were taken for each
tumor (n=2) per group and the percent thresholded area
quantified independently for every stack.
Immunocytochemistry
Pan02 cells were plated on ibidi 8-well mslides (Applied
Biophysics, San Diego, CA) at 10,000 cells per well. Cells were
allowed to adhere overnight at 37uC5 %C O 2. Cells were fixed in
10% formalin for 10 minutes at room temperature then
permeabilized with 0.1% Triton X-100 for 5 minutes at room
temperature. The slides were blocked for 1 hour in 20%
Aquablock (East Coast Bio, North Berwick, ME) before incubation
with primary antibodies rabbit anti-bcatenin (Cell Signaling
Technology, Danvers, MA) or goat anti-mouse SPARC (R&D
Systems, Minneapolis, MN) overnight at 4uC. Slides were
incubated with secondary antibody (1:500) for 1 hour at room
temperature then mounted with DAPI ProLongH Gold antifade
reagent (Invitrogen).
Scratch/Wounding Assay
Cells were plated at a density of 1.5610
5 cells per well in 96-well
plates and allowed to grow to 100% confluency. Serum containing
media was removed, wells washed twice and replaced with serum-
free DMEM. A scratch was then made down the center of each
well with an extra long p10 pipette tip. The most uniform and
consistent scratches were marked and used in the final analysis.
Recombinant SPARC (10 mg/ml), recombinant TGFb1 (250 ng/
ml) and anti-TGFb1,2,3 (10 mg/ml) were prepared in DMEM
0.1% FBS and added to the appropriate wells. Treatments were
performed in duplicate. Images from the center of each well were
taken at times 0 and 6 hours. The wound width (mm) was
measured at a minimum of 20 locations along the wound for each
replicate using NIS Elements AR 2.30 software. The initial wound
width was used to verify consistency in scratches.
Transwell Migration Assay
Cells were serum-starved overnight then plated in duplicate at
20,000 cells/well in 100 ml of serum-free DMEM in the upper
chamber of a 24-well 0.8 mm cell culture insert (BD Falcon, San
Jose, CA). The lower chamber of the 24-well plate received 300 ml
DMEM 0.1% FBS as the chemoattractant. Recombinant SPARC
(10 and 30 mg/ml) was added to the upper chamber, while
recombinant TGFb1 (50, 250 and 500 ng/ml) and anti-
TGFb1,2,3 (5 mg/ml) were added to the bottom chamber. Cells
were allowed to migrate 24 hours at 37uCi n5 %C O 2. Cells were
removed from the upper chamber with cotton swabs. Invading
cells located on the under-side of the membrane were then fixed in
100% cold methanol 10 minutes and stained with hematoxylin
and eosin. Membranes were removed and mounted on slides with
Cytoseal (Thermo Fisher Scientific). A minimum of 10 images per
replicate were taken at 1006total magnification and the number
of invaded cells per field was counted. Cell counts were normalized
to DMEM 0.1% FBS and recorded as % migrating cells.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA). Immunohistochemistry
quantification and all in vitro assays were analyzed with the
unpaired Student’s t test where a p-value less than 0.05 was
considered significant. The survival curves were analyzed with the
Gehan-Breslow-Wilcoxon test.
Supporting Information
Figure S1 Heatmaps from the RT
2 Profiler
TM PCR
Array displaying the TGFb response genes listed in
Table S1. Each box represents a separate gene in the PCR array
and each map is a relative comparison between two groups as
indicated. Fold change log
2 scales are shown below each heatmap.
(TIF)
Figure S2 Pan02 cells have a mesenchymal-like pheno-
type. Fluorescence immunohistochemistry (A–B) and immunocy-
tochemistry (C) were utilized to assess the epithelial versus
mesenchymal nature of Pan02 cells. (A) Frozen tumor sections
were stained with antibody rabbit anti E-Cadherin (red) to mark
epithelial cells. DAPI (blue) marks cell nuclei. Total magnification
(2006) and scale bars (100 mm and 50 mm) are indicated. (B)
Frozen pancreas and tumor sections were stained with antibody
goat anti Vimentin (red) to mark mesenchymal cells. DAPI (blue)
marks cell nuclei. Total magnification (2006) and scale bars
(100 mm) are indicated. (C) Pan02 cells were stained with antibody
rabbit anti b-catenin (red) to visualize its cellular localization.
DAPI (blue) marks cell nuclei. Total magnification (1006) and
scale bars (200 mm) are indicated.
(TIF)
Table S1 The effect of losartan on TGFa ˆ signaling
pathways. RT
2 Profiler PCR Array (SA Biosciences) analysis
of mRNA fold regulation of 84 TGFb response genes in tumors
from SPARC2/2 and SPARC+/+ mice treated with losartan.
Greater than negative two-fold regulation is indicated in italics,
while greater than positive two-fold regulation is indicated in bold
font.
(DOCX)
Table S2 List of antibodies.
(DOCX)
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